These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22577868)

  • 1. Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3 receptor ligands using the DiscoveRx PathHunter™ and Ca2+ release functional assays.
    Riddy DM; Stamp C; Sykes DA; Charlton SJ; Dowling MR
    Br J Pharmacol; 2012 Oct; 167(4):868-80. PubMed ID: 22577868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different response patterns of several ligands at the sphingosine-1-phosphate receptor subtype 3 (S1P(3)).
    Jongsma M; van Unen J; van Loenen PB; Michel MC; Peters SL; Alewijnse AE
    Br J Pharmacol; 2009 Apr; 156(8):1305-11. PubMed ID: 19309361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization.
    Sykes DA; Riddy DM; Stamp C; Bradley ME; McGuiness N; Sattikar A; Guerini D; Rodrigues I; Glaenzel A; Dowling MR; Mullershausen F; Charlton SJ
    Br J Pharmacol; 2014 Nov; 171(21):4797-807. PubMed ID: 24641481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
    Butler J; Lana D; Round O; LaMontagne K
    Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
    Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
    Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
    Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.
    Kennedy PC; Zhu R; Huang T; Tomsig JL; Mathews TP; David M; Peyruchaud O; Macdonald TL; Lynch KR
    J Pharmacol Exp Ther; 2011 Sep; 338(3):879-89. PubMed ID: 21632869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 2 and Selectively Couples to Gα12/13/Rho/ROCK to Induce Myofibroblast Contraction.
    Sobel K; Monnier L; Menyhart K; Bolinger M; Studer R; Nayler O; Gatfield J
    Mol Pharmacol; 2015 Jun; 87(6):916-27. PubMed ID: 25762025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1.
    van Der Lee MM; Bras M; van Koppen CJ; Zaman GJ
    J Biomol Screen; 2008 Dec; 13(10):986-98. PubMed ID: 19036707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics.
    Gonzalez-Cabrera PJ; Hla T; Rosen H
    J Biol Chem; 2007 Mar; 282(10):7254-64. PubMed ID: 17218309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions.
    Gonzalez-Cabrera PJ; Jo E; Sanna MG; Brown S; Leaf N; Marsolais D; Schaeffer MT; Chapman J; Cameron M; Guerrero M; Roberts E; Rosen H
    Mol Pharmacol; 2008 Nov; 74(5):1308-18. PubMed ID: 18708635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictability of peripheral lymphocyte reduction of novel S1P1 agonists by in vitro GPCR signaling profile.
    Xu H; McElvain M; Fiorino M; Henkle B; Sherman L; Xu Y; Tominey E; Kelley K; Adlam M; Bürli R; Siu J; Wong M; Cee VJ
    J Biomol Screen; 2013 Oct; 18(9):997-1007. PubMed ID: 23686102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
    Murakami A; Takasugi H; Ohnuma S; Koide Y; Sakurai A; Takeda S; Hasegawa T; Sasamori J; Konno T; Hayashi K; Watanabe Y; Mori K; Sato Y; Takahashi A; Mochizuki N; Takakura N
    Mol Pharmacol; 2010 Apr; 77(4):704-13. PubMed ID: 20097776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
    Clemens JJ; Davis MD; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.
    Zhu R; Snyder AH; Kharel Y; Schaffter L; Sun Q; Kennedy PC; Lynch KR; Macdonald TL
    J Med Chem; 2007 Dec; 50(25):6428-35. PubMed ID: 17994678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion.
    Hofmann U; Burkard N; Vogt C; Thoma A; Frantz S; Ertl G; Ritter O; Bonz A
    Cardiovasc Res; 2009 Jul; 83(2):285-93. PubMed ID: 19416991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
    Oo ML; Thangada S; Wu MT; Liu CH; Macdonald TL; Lynch KR; Lin CY; Hla T
    J Biol Chem; 2007 Mar; 282(12):9082-9. PubMed ID: 17237497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury.
    Wang L; Sammani S; Moreno-Vinasco L; Letsiou E; Wang T; Camp SM; Bittman R; Garcia JG; Dudek SM
    Crit Care Med; 2014 Mar; 42(3):e189-99. PubMed ID: 24335440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
    Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
    J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis.
    Purschke WG; Hoehlig K; Buchner K; Zboralski D; Schwoebel F; Vater A; Klussmann S
    Biochem J; 2014 Aug; 462(1):153-62. PubMed ID: 24832383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.